Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · University of Turin · +8 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,007
total citations
- FWCI
- 49.36
- Percentile
- 100%
- References
- 33
Citations per year
Authors
30- ASAndrea Sartore‐Bianchi
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
- LTLivio Trusolino
University of Turin, Fondazione Piemontese per la Ricerca sul Cancro Onlus, Candiolo Cancer Institute
- CMCosimo Martino
Candiolo Cancer Institute, Fondazione Piemontese per la Ricerca sul Cancro Onlus
- KBKatia Bencardino
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
- SLSara Lonardi
Istituto Oncologico Veneto
Topics & keywords
Topics
Keywords
- Lapatinib
- Trastuzumab
- Medicine
- KRAS
- Colorectal cancer
- Internal medicine
- Oncology
- Cetuximab
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.